At present, the renal community suffers from a limited array of noninvasive tools in routine clinical use that can accurately and rapidly identify acute kidney injury (AKI) and generate useful prognostic information to help guide current therapy and anticipate major subsequent events, some of which may require substantial interventions, such as initiating renal replacement therapy.

In the March issue of Kidney News, a study by Axelrod et al. (1) was featured that analyzed the costs of kidney transplantation. The study found that costs are increasing substantially, mostly because of the increased complexity of transplant recipients and a lack of changes in the reimbursement model by payers.

In the assessment of chronic kidney disease–mineral bone disorder (CKD-MBD), serial measurements of serum calcium, phosphorus, and parathyroid hormone (PTH) occur, and attempts are made to bring these levels into the normal range. However, the optimal level of PTH in dialysis patients is not known.

In the therapy of hypertension, diabetes, or dyslipidemia or the attempt to prevent solid organ transplant rejection, it is a well recognized strategy to use a number of complementary pharmacologic approaches to address the fundamental goal, whether it is achieving better control of blood pressure (BP), blood sugar, or blood lipids, or long-term allograft survival.

For patients who have had acute kidney injury (AKI), the long-term risk of renal progression remains high even if their kidney function ultimately returns to normal, suggests a new study in Kidney International.